Poxyirdiae
[0058]
Abstract
The compositions of this invention may be used to prevent (propylaxis), treat (ameliorate symptoms, shorten duration of illness, lessen severity), or cure viral infections caused by Poxyiridae. Poxiviridae infections that may be treated by this invention include both vertebrate poxviruses (subfamily Chordopoxyirinae) and insect poxviruses (Entomopoxyirinae, e.g., Entomopoxyirinae A, B, and C). Vertebrate poxviruses include without limitation those members of the genera: Orthopoxvirus (e.g., camelpox, cowpox, ectromelia, monkeypox, racconpox, skunkpox, taterapox, Uasin Gishu, vaccinia, variola (small pox), and volepox), Parapoxvirus (Auzduk disease, chamois, contagious eethyma, orf, pseudocoxpox, parapox of deer, and sealpox); Avipoxvirus (e.g., canarypox, fowlpox, juncopox, pigeonpox, psittacinepox, quailpox, peacockpox, sparrowpox, peguinpox, starlingpox and turkeypox), Capripoxvirus (e.g., goatpox, lumpy skin disease, and sheeppox), Leporipoxvirus (e.g., Hare fibroma, myxoma, rabbit fibroma,
squirrel fibroma), Suipoxvirus (e.g., swinepox), and Molluscipoxvirus (e.g., Molluscum contagiosum).